PHG

Business Context and Reporting Period

Company: Koninklijke Philips N.V. (Royal Philips)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: First Quarter ended March 31, 2026
Release Date: May 6, 2026

Philips reported a strong start to 2026, characterized by disciplined execution in an uncertain macro-environment. The company highlighted growth across all segments, led by North America and Europe, and continued progress on its strategic pillars of segment-specific strategies, platform-based innovations, and productivity.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Improvement: Income from operations increased by EUR 87 million (57% increase) to EUR 241 million, driven by operational improvements and lower restructuring/acquisition charges compared to Q1 2025.
• Margin Expansion: Adjusted EBITA margin improved by 40 basis points to 9.0%, supported by sales growth, gross margin from innovations, and productivity, despite headwinds from tariffs and cost inflation.
• Cash Flow Recovery: Operating cash flow turned positive at EUR 188 million, a significant improvement from the negative EUR 933 million in Q1 2025. This was primarily due to the absence of the EUR 1.025 billion payment for Philips Respironics recall-related settlements made in the prior year.
• Segment Performance:
  • Personal Health: Comparable sales grew 9% with Adjusted EBITA margin rising to 15.8%.
  • Diagnosis & Treatment: Comparable sales grew 2% with Adjusted EBITA margin at 9.8%.
  • Connected Care: Comparable sales grew 3%, but Adjusted EBITA margin declined 60 basis points to 2.9% due to tariff and inflation impacts.
• Charges: Restructuring and acquisition-related charges totaled EUR 61 million, down from EUR 143 million in Q1 2025. This included a EUR 42 million gain from the release of an acquisition-related provision.

Guidance, Outlook, and Risks

Full-Year 2026 Outlook (Reiterated)

• Comparable Sales Growth: 3% - 4.5%
• Adjusted EBITA Margin: 12.5% - 13.0%
• Free Cash Flow: EUR 1.3 - 1.5 billion

Management Commentary: CEO Roy Jakobs emphasized disciplined execution to offset external pressures like tariffs and inflation. The company is on track to deliver EUR 1.5 billion in savings under its 2026-2028 productivity program, having achieved EUR 126 million in savings in Q1 alone.

Capital Allocation: Philips announced a plan to repurchase up to 4 million shares (approx. EUR 91 million) to cover long-term incentive plan obligations. Repurchases are expected in Q2/Q3 2026 with delivery in Q4 2028.

Risks and Contingencies:

• Macro Environment: Outlook includes known tariff impacts but excludes potential International Emergency Economic Powers Act (IEEPA) tariff refunds.
• Legal Proceedings: Outlook excludes ongoing Philips Respironics-related proceedings, including the US Department of Justice investigation.
• Geopolitical: Risks include macro-economic changes, geopolitical tensions (Ukraine, Middle East), and supply chain resilience.

Investor Verification Checklist

• Respironics Liability: Verify the status of the US DOJ investigation and potential financial impact of ongoing Respironics-related proceedings, which are excluded from the current outlook.
• Tariff Exposure: Assess the sensitivity of the 2026 margin guidance to further increases in tariffs or cost inflation, particularly in the Connected Care segment.
• Share Repurchase Execution: Monitor the timing and execution of the announced EUR 91 million share repurchase program and its impact on liquidity.
• Productivity Targets: Track progress against the EUR 1.5 billion savings target for the 2026-2028 period to ensure margin expansion goals are met.
• Regulatory Approvals: Confirm the commercial uptake of newly approved AI-powered innovations (SmartHeart, DeviceGuide) and their contribution to future revenue growth.